# St. Petersburg State Pavlov Medical University: Phase 2 study completed, 37 enrolled (Hodgkin Lymphoma)

**Score:** 70/100

| Field | Value |
|---|---|
| Sponsor | St. Petersburg State Pavlov Medical University |
| Sponsor type | Academic and hospital |
| Study | PET-Adapted Low-Dose Nivolumab With NICE-40 for Relapsed/Refractory Classical Hodgkin Lymphoma |
| NCT ID | NCT04981899 |
| Phase | Phase 2 |
| Status | completed |
| Conditions | Hodgkin Lymphoma |
| Intervention types | drug |
| Target enrollment | 37 |
| Site countries | Russia |
| Posted | 2021-07-29 |
| Planned start | 2021-03-01 |
| Event | Completed |
| Event date | 2026-09-15 |
| Last update posted | 2026-10-28 |

## Why this score
- Posted in the last two weeks.
- Completed: closeout, analysis and the next study ahead.
- Phase 2: multi-site, larger budget.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT04981899). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.